Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on MEI Pharma (MEIP – Research Report) today and set a price target of $4.00. The company’s shares closed last Friday at $0.24.
R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Caribou Biosciences, and MEI Pharma. According to TipRanks, R. Cann has an average return of -2.0% and a 38.62% success rate on recommended stocks.
MEI Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See Insiders’ Hot Stocks on TipRanks >>
MEIP market cap is currently $32.46M and has a P/E ratio of -0.54.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
Read More on MEIP:
